Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. - Wikidata - awgldk - TriplyDB

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

http://www.wikidata.org/entity/Q34619348

about

Melanoma-associated antigen synthesized in vitro for active specific immunotherapy.From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.Advances in cancer vaccine development.Natural and induced human antibody response to cancer.Innovations and strategies for the development of anticancer vaccines.Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.Immunotherapy for melanoma.Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.Possibilities for active immunotherapy of human cancer.Recent Development in Carbohydrate Based Anti-cancer Vaccines.Immunotherapy for melanoma: current status and perspectives.Chemical Synthesis of GM2 Glycans, Bioconjugation with Bacteriophage Qβ, and the Induction of Anticancer Antibodies.Glycoimmunomics of human cancer: current concepts and future perspectives.Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.Epitope- and antigen-specific cancer vaccines.Role of gangliosides in active immunotherapy with melanoma vaccine.Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Toward automated oligosaccharide synthesis.Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies.Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies.Modulation of cancer patients' immune responses by anti-idiotypic antibodies.Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma.Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.Melanoma, immune surveillance, and immunotherapy.Active specific immunotherapy against adenocarcinomas.Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer.Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines.Recognition of autoantigens by patients with melanoma.Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans.Immunotherapy of melanoma: current status and prospects for the future.Synthesis and Evaluation of GM2-Monophosphoryl Lipid A Conjugate as a Fully Synthetic Self-Adjuvant Cancer Vaccine.Tumor recognition by the cellular immune system: new aspects of tumor immunology.Update on active specific immunotherapy with melanoma vaccines.Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines.Recent advances in the treatment of malignant melanoma with gene therapy.

P2860

Q33188234-9DE65F42-8458-4E0F-A44B-ABE11108F153 Q33466255-58851E12-41FB-4CC0-A2D1-3E198E7931D2 Q33557110-EC6C0B3E-C1E0-424C-B60D-FF0671F4D008 Q33603404-C0898E84-C449-481C-928B-582B422062A0 Q33931150-CA1FC1DC-5A43-443A-948E-2E436C020D94 Q34182039-5CE7524D-40F9-4334-A7FD-AF9F02CC2167 Q34504625-685D6424-218A-42A7-814A-7DE6E207C5C5 Q34573035-433A2E10-D0F4-4035-A7B1-D00D7431D508 Q35079733-03EF813C-DFB9-43BC-961B-049AD01AA453 Q35326752-D0D64434-7C07-45CC-B171-B0CE61567BEE Q35854131-A77E7EF8-4AC4-4A2C-B60D-CAFF940DAF39 Q36453216-0EAA45A3-0403-4822-97EE-36683302C3E8 Q36501284-C657A4EC-5910-461E-B262-DBF8FC760A1E Q36768301-F4E3B64F-C0E8-49CF-BCB6-A4096C90ACFE Q36781607-132582D9-90C5-4D09-A865-13F6C761AA34 Q36856279-45885212-F265-4A2C-A7C3-DE04E8A503B8 Q36930069-2D0E9FD3-035D-4921-8F22-B61DAA0E4EE9 Q36930077-65528DEC-171B-4DA3-8AA7-119C5DB687ED Q37053497-C48F6E6B-AF0F-4A0E-A0A2-D385E62371DD Q37608314-BBA2F82E-5A17-45D3-BA16-968BBD238170 Q37952804-F42736A5-D806-4FBF-B666-3DBA25DCB196 Q37962848-AFDA3DF0-C68C-4837-9CC6-81681095E65B Q37993590-BA497A33-0133-4214-A527-9D1D2BA3D71D Q38195895-7751B3C2-FA7B-4CF6-BA71-D28E2D3D27EA Q38246922-7F3A4FD2-C21C-4396-AADF-671E66C68FF1 Q38569655-321802F9-7193-4CC6-9AFD-58370379D68E Q38784095-BD4ADC6A-8092-440A-82C0-05D41001AFF6 Q40114484-65641D8F-76D4-4577-97FE-5DCAB603D86A Q40335389-4771BD18-3896-4304-83AA-E1CC0FA341C6 Q40385527-53406B2F-0A2E-4D4C-8D77-86868A45DC04 Q40517098-F68FAAB5-1DA1-4C5D-A5E2-8A292FEA3D20 Q40714768-31469F8F-AC98-41AF-83D0-070FBCA1B426 Q40844530-208CFDE5-D81D-4AD2-BB34-5A3131D78FB9 Q40879087-D7A698A3-DC6C-439B-955A-3DF338EE1E39 Q40899717-13896C14-C24B-4175-AAC3-5A6A4AE65DBC Q41194257-8E442749-D4FC-4995-BF60-0BB6DD285FFF Q41455911-18C7A6E0-E957-4C82-BAA5-11BE462B3A3D Q41589321-35BB9490-090F-4706-B6B8-5DC93F9BB15A Q41605409-9BFACABB-8158-41F2-B1A4-5D054077A12B Q41657233-7426C8A3-9ADC-40D6-8EF2-89D18ADD78B6

P2860

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

http://www.wikidata.org/entity/Q34619348

description

1987 nî lūn-bûn

@nan

1987 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1987 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1987年の論文

@ja

1987年論文

@yue

1987年論文

@zh-hant

1987年論文

@zh-hk

1987年論文

@zh-mo

1987年論文

@zh-tw

1987年论文

@wuu

name

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

@ast

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

@en

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

@nl

type

label

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

@ast

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

@en

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

@nl

prefLabel

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

@ast

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

@en

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

@nl

P1433

Q34619348-FA61D32E-202B-41D6-9E9D-6207D27092B5

P1476

Q34619348-AF55EEB2-243A-471B-9324-AB106982282D

P2093

Q34619348-261A0A07-3CE1-4BD1-BF17-A3415B2539C3

Q34619348-432CAE0D-186C-416F-A8AA-D465714623C2

Q34619348-4DEDFAA4-4C41-499D-85A6-62815C73481F

Q34619348-840C55C8-5BB2-44F4-9930-315B89AB931B

Q34619348-927DB3EA-D894-4D07-9C8D-318B32D96EE6

Q34619348-D80FB7F7-F8CC-45B1-BC38-62B62DB48818

P2860

Q34619348-0035E2B6-BFE4-4441-B9DF-6577B915F87D

Q34619348-1AC4BA36-554D-4A4F-B74B-2EDFE134DFD2

Q34619348-1DAEBEEB-3EE4-4D73-BF99-A5F4E8DD6D5D

Q34619348-23A87D34-3DCB-49F2-ADD1-F7E4DFD48E01

Q34619348-281B0814-7FFA-4C00-ADD6-38A0278711D4

Q34619348-2B1CC9B4-8BBE-433C-AD24-295B1B070EB0

Q34619348-31D29FF0-524B-43B1-8A71-6D99927F3F45

Q34619348-50A0DB90-639B-4172-B3EA-E26364EE5210

Q34619348-52F459FA-D014-40A1-932E-EEDF420A1734

Q34619348-5DFD658E-317B-4229-87B0-F024E922DFE5

P304

Q34619348-96363937-9F88-48A8-8F35-D53651D33548

P31

Q34619348-99BAA198-8ED8-40B8-9490-725A515A9C75

P356

Q34619348-746232C3-115D-48A7-A7FB-676CD1F173AE

P407

Q34619348-859FCA00-DB56-445E-B8BB-4C97408F6EFD

P433

Q34619348-92E03AF8-1312-4520-AB69-BB54E1DBA2CB

P478

Q34619348-3BB3B23A-375E-4AFB-833A-356812425B83

P577

Q34619348-58DA42AC-14D9-457F-8C64-DDADEC644F29

P5875

Q34619348-BE0A7E4E-C48E-4C65-ACF5-5EBEB0892F26

P698

Q34619348-9DC5255D-BD10-4312-8422-D3102D25B66D

P921

Q34619348-5B1B4B97-1EB5-44A6-8D3A-10538CE5DBCA

Q34619348-9071FA31-FA6E-4340-BE96-DCE2EBB364C2

P932

Q34619348-4E6330DD-4E1F-4E92-A2ED-17657E31DDEC

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.

@en

P2093

E J Natoli

http://www.w3.org/2001/XMLSchema#string

E Stockert

http://www.w3.org/2001/XMLSchema#string

H F Oettgen

http://www.w3.org/2001/XMLSchema#string

L J Old

http://www.w3.org/2001/XMLSchema#string

M J Calves

http://www.w3.org/2001/XMLSchema#string

P O Livingston

http://www.w3.org/2001/XMLSchema#string

P2860

Cell-surface antigens of melanoma recognized by human monoclonal antibodies

THE GANGLIOSIDES.

T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.

Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2

Human melanoma antigen AH is an autoantigenic ganglioside related to GD2.

Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody

Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.

Ganglioside GM2 as a human tumor antigen (OFA-I-1).

Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells.

Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture.

P304

2911-2915

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.84.9.2911

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P577

1987-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

19684582

http://www.w3.org/2001/XMLSchema#string

P698

3472242

http://www.w3.org/2001/XMLSchema#string

P921

P932

304770

http://www.w3.org/2001/XMLSchema#string